Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

• Published in: Expert review of pharmacoeconomics & outcomes research Vol. 15; no. 4; p. 579
• Main Authors: Carrato, Alfredo, García, Pilar, López, Rafael, Macarulla, Teresa, Rivera, Fernando, Sastre, Javier, Gostkorzewicz, Joana, Benedit, Patricia, Pérez-Alcántara, Ferran
• Format: Journal Article
• Language: English
• Published: England 2015
• Subjects: Albumins - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cost-Benefit Analysis; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel - administration & dosage; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - economics; Pancreatic Neoplasms - pathology; Quality-Adjusted Life Years; Spain; Spain; nab-paclitaxel; pancreatic; cancer; cost; Spain

The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy data were obtained from the MPACT study and were...